| Literature DB >> 26847086 |
Satu Sandell1,2,3, Sanna Huovinen4,5, Johanna Palmio6,4, Olayinka Raheem4,7, Mikaela Lindfors4, Fang Zhao7, Hannu Haapasalo4,5, Bjarne Udd6,4,8,9.
Abstract
INTRODUCTION: Limb girdle muscular dystrophies are a large group of both dominantly and recessively inherited muscle diseases. LGMD1D is caused by mutated DNAJB6 and the molecular pathogenesis is mediated by defective chaperonal function leading to impaired handling of misfolded proteins which normally would be degraded. Here we aim to clarify muscle pathology of LGMD1D in order to facilitate diagnostic accuracy. After following six Finnish LGMD1D families, we analysed 21 muscle biopsies obtained from 15 patients at different time points after the onset of symptoms. All biopsies were obtained from the lower limb muscles and processed for routine histochemistry, extensive immunohistochemistry and electron microscopy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26847086 PMCID: PMC4743201 DOI: 10.1186/s40478-016-0276-9
Source DB: PubMed Journal: Acta Neuropathol Commun ISSN: 2051-5960 Impact factor: 7.801
Clinical summary
| Patient | Sex | Age of onset | Age at muscle biopsy | Symptoms (when examined) | CK | EMG | Other |
|---|---|---|---|---|---|---|---|
| FF1 | |||||||
| III-6 | M | 50 | 74 | ll severe, ul mild | 400 | na | |
| III-8 | F | 60 | 69 | ll mild, ul mild | 187 | myopathic | |
| III-12 | F | 35 | 47, 63, 72 | ll severe, ul moderate | 338 | myopathic | |
| IV-7 | M | 34 | 46, 48 | ll moderate, ul moderate | 789 | myopathic | dysphagia |
| V-8 | M | 30 | 38 | ll mild, no ul | 820 | myopathic | |
| IV-9 | F | 30 | 38, 42 | ll moderate, ul mild | 375 | myopathic | |
| IV-10 | M | 20 | 44, 49 | ll moderate, ul mild | 175 | myopathic | |
| FF2 | |||||||
| III-4 | F | 50 | 63 | ll mild, no ul | 520 | myopathic | |
| FF3 | |||||||
| IV-1 | M | 38 | 49, 51 | ll, severe, ul moderate | 600 | myopathic | dysarthria, ll pain |
| FF4 | |||||||
| III-2 | F | 40 | 62 | ll mild, slow course | “normal” | myopathic | |
| IV-1 | M | 28 | 31 | ll mild, ul mild | 1900 | myopathic | |
| FF5 | |||||||
| IV-1 | M | 30 | 47 | ll severe, ul mild | “normal” | myopathic | dysphagia |
| FF6 | |||||||
| IV-1 | M | 40 | 51 | ll, severe, ul moderate | 800 | myopathic |
ll, lower limb; ul, upper limb. Clinical findings at the time of clinical examination, within one year of muscle biopsy sample time (or latest biopsy, if many). Creatine kinase (CK) normal upper limits 400 for men, 210 for women
Fig. 1Pedigrees of Finnish families FF1–6. Black figures represent affected individuals
Antibodies used in immunohostochemical stainings, their dilutions and supplier
| Antibody | Dilution | Supplier |
|---|---|---|
| Myotilin | 1:50 | Leica Biosystems, Novocastra |
| Alpha B crystallin | 1:10 | Leica Biosystems, Novocastra |
| Desmin | 1:800 | Biogenex |
| Dystrophin 2 (c-terminus) | 1:100 | Leica Biosystems, Novocastra |
| SMI-31 | 1:1000 | Biosite |
| SMI-310 | 1:400 | Abcam |
| TDP-43 | 1:175 | Proteintech Europe |
| P62 (SQSTM1) | 1:100 | Santa Cruz Biotechnology |
| Ubiquitin | 1:300 | Dako |
| LAMP2 | 1:50 | Southern Biotech |
| LC3 | 1:50 | Novus Biologicals |
| LC3B | 1:50 | Cell Signaling technology |
| VCP | 1:600 | Thermo Scientific |
| FHL-1 | 1:200 | Lifespan biosciences |
| DNAJB6 | 1:100 | Abnova |
| HSPB8 | 1:200 | Abcam |
| BAG3 | 1:800 | Proteintech Europe |
| Proteasome | 1:30 | Atlas antibodies |
| Beta-amyloid | 1:30 | Leica Biosystems, Novocastra Life |
| Amyloid precursor protein | 1:50 | Biosciences |
| Wip1 | 1:50 | Sigma |
| Dystrophin 1 (rod domain) | 1:40 | Leica Biosystems, Novocastra |
| Dystrophin 2 (c-terminus) | 1:100 | Leica Biosystems, Novocastra |
| Dystrophin 3 (N-terminus) | 1:20 | Leica Biosystems, Novocastra |
| Dysferlin | 1:200 | Leica Biosystems, Novocastra |
| α-Sarcoglycan | 1:100 | Leica Biosystems, Novocastra |
| β-Sarcoglycan | 1:100 | Leica Biosystems, Novocastra |
| γ-Sarcoglycan | 1:15 | Leica Biosystems, Novocastra |
| α-Dystroglycan | 1:200 | Millipore, Upstate |
| Caveolin 3 | 1:150 | Santa Cruz Biotechnology |
| Merosin Laminin Alpha 2 Chain | 1:500 | USBiological |
| Utrophin | 1:20 | Leica Biosystems, Novocastra |
| Spectrin | 1:50 | Leica Biosystems, Novocastra |
Fig. 2a On H&E staining on gastrocnemius lateralis muscle of a 51-year-old male (FF3, IV-1) mild endomysial fibrosis as well as fiber size variation, internal nuclei, one atrophic rimmed vacuolated fiber (arrow in the middle) and small centrally located myofibrillar aggregates mainly in non-atrophic fibers (arrows in left corner) are evident. b. In modified trichrome staining of the same muscle the aggregates appear as darker stained areas
Myopathological findings
| Muscle | Neurogenic fiber type grouping | Fiber type predominance | Fiber size variation | Fibrosis and fatty degeneration | Increase of internal nuclei | Fiber splitting | Necrosis | Lymphocyte infiltrates | Fiber regeneration | Rimmed vacuoles | Cytoplasmic myofibrillar inclusions | Core-like lesions | Rubbed-out fibers | Moth-eaten | Lobulated fibers | Ragged red fibers | COX– fibers | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FF1 | |||||||||||||||||||
| III-6 | VL | – | + | ++ | + | + | – | – | – | + | + | + | – | ++ | + | – | – | ||
| III-8 | S | (+) | – | ++ | ++ | ++ | ++ | – | – | + | ++ | ++ | – | – | – | – | – | ||
| III-12 | VL | – | + | (+) | + | – | – | – | – | + | (+) | + | – | – | – | – | – | ||
| GLU | – | + | (+) | + | – | + | – | + | + | + | ++ | + | – | – | – | – | |||
| VL | – | (+) | + | + | – | + | + | + | + | ++ | – | – | + | – | – | – | |||
| IV-7 | GM | – | – | + | + | + | + | + | + | – | + | + | +++ | – | – | – | – | – | |
| GM | – | – | ++ | ++ | ++ | ++ | – | + | + | ++ | ++ | + | – | + | – | – | – | ||
| IV-8 | GM | – | – | + | – | + | + | + | + | + | + | + | + | – | + | + | – | – | |
| IV-9 | VL | – | + | + | – | + | + | + | + | + | + | + | – | – | + | – | – | – | |
| VL | + | – | ++ | + | + | – | – | – | – | + | + | – | – | – | (+) | – | (+) | ||
| IV-10 | VL | – | – | – | – | – | – | – | – | – | + | (+) | + | – | – | – | – | – | |
| VL | – | + | + | – | + | – | – | – | – | + | + | + | – | – | – | – | – | ||
| FF2 | |||||||||||||||||||
| III-4 | VL | – | + | – | + | – | – | – | – | + | + | – | – | – | – | – | (+) | ||
| III-5 | VL | – | + | – | + | – | – | – | – | + | ++ | – | – | – | – | – | (+) | ||
| III-7 | VL | – | ++ | ++ | +++ | + | + | + | + | + | + | + | – | + | – | – | – | ||
| FF3 | |||||||||||||||||||
| IV-1 | VL | + | – | ++ | + | +++ | + | + | + | – | + | ++ | + | – | + | – | – | – | |
| GL | – | – | ++ | + | ++ | + | ++ | + | – | + | ++ | ++ | – | + | + | – | (+) | ||
| FF4 | |||||||||||||||||||
| III-2 | VL | – | + | ++ | ++ | ++ | + | + | – | – | + | + | + | – | + | – | – | – | |
| IV-1 | VL | – | – | (+) | – | + | – | + | – | + | + | + | ++ | – | + | – | – | – | |
| FF5 | |||||||||||||||||||
| IV-1 | VL | – | + | ++ | ++ | ++ | + | + | + | – | ++ | + | + | – | – | +++ | – | – | |
| FF6 | |||||||||||||||||||
| IV-1 | VL | + | – | ++ | ++ | + | – | – | – | – | + | + | – | – | + | + | – | (+) | |
Internal nuclei amount assessed as: –, absent; (+), existent in < 1 %; +, existent up to 5 %; ++, existent in 6–20 %; +++, existent in over 20 % of the fibers. Fibrosis and fatty degeneration: –, no fibrosis, fatty degeneration; +, mildly increased; ++, moderately increased
Fig. 3a, c, d. Vastus lateralis muscle of a 72-year-old female (FF1, III-12): moderate or strong expression of proteins myotilin (a), desmin (c) and alphaB-crystallin (d) in the myofibrillar lesions with aggregates on immunohistochemistry. b. Congo red staining viewed through Texas-red filters shows numerous congophilic fluorescent deposits in muscle fibers. e. Dystrophin-2 showed ectopic expression of mild or moderate intensity in the same regions. f, g, h. The protein accumulations showing CASA complex proteins BAG3 (f), HSPB8 (g), and DNAJB6 (h)
Immunohistochemical findings
| Muscle | Myotilin | α-BC | Desmin | DYS-2 | SMI-31 | TDP-43 | p62 | Ubiquitin | LAMP-2 | VCP | FHL1 | Membr prot | LC3 | HSPB8 | DNAJB6 | Ubiquilin2 | Cathepsin B | Filamin C | BAG3 | α-actinin | Teletonin | Actin | SERCA | α-tubulin | SMI310 | Proteasome | β-amyloid | APP | WIP1 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FF1 | |||||||||||||||||||||||||||||||
| III-6 | VL | + | – | – | + | – | – | – | |||||||||||||||||||||||
| III-8 | S | ++ | ++ | + | ++ | ++ | ++ | + | |||||||||||||||||||||||
| III-12 | VL | ||||||||||||||||||||||||||||||
| GLU | + | + | |||||||||||||||||||||||||||||
| VL | + | + | + | + | – | – | – | ||||||||||||||||||||||||
| IV-7 | GM | ++ | ++ | + | ++ | ++ | |||||||||||||||||||||||||
| GM | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | – | ++ | – | ++ | ++ | – | – | ++ | + | – | ++ | + | – | – | – | ||||||||
| IV-8 | GM | ++ | ++ | ++ | + | ++ | ++ | ++ | – | – | – | ++ | – | – | – | ++ | + | – | – | ++ | + | – | – | – | |||||||
| IV-9 | VL | – | + | + | + | – | – | + | – | – | – | ||||||||||||||||||||
| VL | + | + | + | – | ++ | ++ | – | ++ | + | + | – | – | – | ||||||||||||||||||
| IV-10 | VL | ++ | ++ | + | + | – | + | + | – | – | |||||||||||||||||||||
| VL | ++ | ++ | + | + | – | + | + | ++ | – | – | + | – | – | – | – | + | + | – | + | – | – | – | |||||||||
| FF2 | |||||||||||||||||||||||||||||||
| III-4 | VL | – | – | ||||||||||||||||||||||||||||
| III-5 | VL | – | – | – | |||||||||||||||||||||||||||
| III-7 | VL | + | + | + | + | ||||||||||||||||||||||||||
| FF3 | |||||||||||||||||||||||||||||||
| IV-1 | VL | – | ++ | – | |||||||||||||||||||||||||||
| GL | ++ | ++ | ++ | + | ++ | – | |||||||||||||||||||||||||
| FF4 | |||||||||||||||||||||||||||||||
| III-2 | VL | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | – | ++ | – | ++ | + | + | ++ | + | – | ++ | + | – | + | |||||||||
| IV-1 | VL | + | ++ | ++ | |||||||||||||||||||||||||||
| FF5 | |||||||||||||||||||||||||||||||
| IV-1 | VL | ++ | ++ | + | + | ++ | ++ | ++ | – | – | – | – | + | + | + | ++ | – | – | – | ||||||||||||
| FF6 | |||||||||||||||||||||||||||||||
| IV-1 | VL | + | – | + | – | +/– | +/– | + | + | – | + | – | + | + | +/– | – | |||||||||||||||
–, normal, no immunoreactivity; +, present immunoreactivity; ++, prominent immunoreactivity
Fig. 4a, b, c, d, e. The same patient and muscle as in Fig. 3. The rimmed vacuoles showed material with reactivity for several markers of defect degradation and autophagic processing such as ubiquitin (a), VCP (b), TDP-43 (c), p62 (d) and SMI-31 (e). f, g. The rimmed vacuolar regions of local degeneration filled with autophagosomes, shown by LC3 (f) reactivity, components of mature lysosomes expressing LAMP2 (g)
Fig. 5Electron micrograph from vastus lateralis muscle biopsy of a 69-year-old female (FF1, III-8) shows loss of the normal sarcomeric structure with excess dispersed wavy Z-disk material